IP Library Granted Patent US 11,260,064
Granted Patent B2
US 11,260,064 · App. 16/244,219 · Granted Mar 1, 2022

Stable corticosteroid compositions

Inventor: Ramalingeswar Kasina (Lexington, MA)
Assignee: VIROPHARMA BIOLOGICS LLC
A61K31/58A61K47/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,064
App. No.
16/244,219
Granted
Mar 1, 2022
Kind
B2
Abstract

The invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant.

Claims (12)

1. A pharmaceutical composition comprising budesonide, an antioxidant in an amount of from about 0.05% to about 0.5% w/w of the composition, wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate, and a flavoring agent, a sweetener, or a combination thereof, wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation, and wherein the pharmaceutical composition is for oral administration.

2. The pharmaceutical composition of claim 1 , wherein the composition comprises less than 0.3% impurities formed by oxidative degradation after one month of storage.

3. The pharmaceutical composition of claim 2 , wherein the composition does not discolor after one month of storage.

4. The pharmaceutical composition of claim 1 , wherein the composition comprises less than 0.3% impurities formed by oxidative degradation and does not discolor after two months of storage.

5. The pharmaceutical composition of claim 1 , wherein the composition comprises less than 0.3% impurities formed by oxidative degradation and does not discolor after three months of storage.

6. The pharmaceutical composition of claim 1 , wherein after two months of storage the composition comprises less than 0.2% impurities formed by oxidative degradation.

7. The pharmaceutical composition of claim 2 , wherein the impurities formed by oxidative degradation comprise 21-dehydrobudesonide.

8. The pharmaceutical composition of claim 1 having a pH of between about 4 and about 5.2.

9. The pharmaceutical composition of claim 1 , further comprising a preservative.

10. The pharmaceutical composition of claim 9 , wherein the preservative is selected from sodium benzoate and potassium sorbate.

11. The pharmaceutical composition of claim 1 , wherein the combination of the ascorbic acid and the salt of ascorbate is present in an amount of from about 0.1% to about 0.5% w/w of the composition.

12. A kit for treating or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract in a subject in need thereof, comprising a pharmaceutical composition comprising budesonide, an antioxidant in an amount of from about 0.05% to about 0.5% w/w of the composition, wherein the antioxidant comprises a combination of ascorbic acid and a pharmaceutically acceptable salt of ascorbate, and a flavoring agent, a sweetener, or a combination thereof, wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation, and wherein the pharmaceutical composition is for oral administration.

Assignments (4)
MERGER Recorded Jul 9, 2021
From: MERITAGE PHARMA, INC.
To: SHIRE VIROPHARMA LLC
Reel/Frame 056802/0233 →
MERGER Recorded Jul 9, 2021
From: SHIRE VIROPHARMA LLC
To: VIROPHARMA BIOLOGICS LLC
Reel/Frame 056802/0426 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: KASINA, RAMALINGESWAR
To: MERITAGE PHARMA, INC.
Reel/Frame 050718/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: KASINA, RAM
To: MERITAGE PHARMA, INC.
Reel/Frame 049793/0920 →
Continuity (2)
Provisional Application 62616213 · Jan 11, 2018
Related Publication 20190209587A1 · Jul 11, 2019